OpenLB
Open Library of Bioscience

DNA Methyltransferase 3A: A Significant Target for the Discovery of Inhibitors as Potent Anticancer Drugs.

Abstract

Keywords

References

1. Moore L.D.; Le T.; Fan G.; DNA methylation and its basic function. Neuropsychopharmacology 2013,38(1),23-38 [DOI: 10.1038/npp.2012.112]
2. You J.S.; Jones P.A.; Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 2012,22(1),9-20 [DOI: 10.1016/j.ccr.2012.06.008]
3. Hoang N.M.; Rui L.; DNA methyltransferases in hematological malignancies. J Genet Genom 2020,47(7),361-372 [DOI: 10.1016/j.jgg.2020.04.006]
4. Zhang H.; Ying H.; Wang X.; Methyltransferase DNMT3B in leukemia. Leuk Lymphoma 2020,61(2),263-273 [DOI: 10.1080/10428194.2019.1666377]
5. Hamidi T.; Singh A.K.; Chen T.; Genetic alterations of DNA methylation machinery in human diseases. Epigenomics 2015,7(2),247-265 [DOI: 10.2217/epi.14.80]
6. Li E.; Zhang Y.; DNA methylation in mammals. Cold Spring Harb Perspect Biol 2014,6(5),a019133 [DOI: 10.1101/cshperspect.a019133]
7. Barau J.; Teissandier A.; Zamudio N.; Roy S.; Nalesso V.; Hérault Y.; Guillou F.; Bourc’his D.; The DNA methyltransferase DNMT3C protects male germ cells from transposon activity. Science 2016,354(6314),909-912 [DOI: 10.1126/science.aah5143]
8. Jia D.; Jurkowska R.Z.; Zhang X.; Jeltsch A.; Cheng X.; Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007,449(7159),248-251 [DOI: 10.1038/nature06146]
9. Fernández-Sanlés A.; Sayols-Baixeras S.; Subirana I.; Sentí M.; Pérez-Fernández S.; de Castro Moura M.; Esteller M.; Marrugat J.; Elosua R.; DNA methylation biomarkers of myocardial infarction and cardiovascular disease. Clin Epigenet 2021,13(1),86 [DOI: 10.1186/s13148-021-01078-6]
10. Teitell M.; Richardson B.; Dna methylation in the immune system. Clin Immunol 2003,109(1),2-5 [DOI: 10.1016/S1521-6616(03)00224-9]
11. Weng Y.L.; An R.; Shin J.; Song H.; Ming G.; DNA modifications and neurological disorders. Neurotherapeutics 2013,10(4),556-567 [DOI: 10.1007/s13311-013-0223-4]
12. Arguelles A.O.; Meruvu S.; Bowman J.D.; Choudhury M.; Are epigenetic drugs for diabetes and obesity at our door step? Drug Discov Today 2016,21(3),499-509 [DOI: 10.1016/j.drudis.2015.12.001]
13. Michalak E.M.; Burr M.L.; Bannister A.J.; Dawson M.A.; The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol 2019,20(10),573-589 [DOI: 10.1038/s41580-019-0143-1]
14. Gaudet F.; Hodgson J.G.; Eden A.; Jackson-Grusby L.; Dausman J.; Gray J.W.; Leonhardt H.; Jaenisch R.; Induction of tumors in mice by genomic hypomethylation. Science 2003,300(5618),489-492 [DOI: 10.1126/science.1083558]
15. Pan Y.; Liu G.; Zhou F.; Su B.; Li Y.; DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med 2018,18(1),1-14 [DOI: 10.1007/s10238-017-0467-0]
16. Ali S.R.; Jordan M.; Nagarajan P.; Amit M.; Nerve density and neuronal biomarkers in cancer. Cancers 2022,14(19),4817 [DOI: 10.3390/cancers14194817]
17. Medina-Franco J.L.; Méndez-Lucio O.; Dueñas-González A.; Yoo J.; Discovery and development of DNA methyltransferase inhibitors using in silico approaches. Drug Discov Today 2015,20(5),569-577 [DOI: 10.1016/j.drudis.2014.12.007]
18. Robertson K.D.; Uzvolgyi E.; Liang G.; Talmadge C.; Sumegi J.; Gonzales F.A.; Jones P.A.; The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999,27(11),2291-2298 [DOI: 10.1093/nar/27.11.2291]
19. Xie S.; Wang Z.; Okano M.; Nogami M.; Li Y.; He W.W.; Okumura K.; Li E.; Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene 1999,236(1),87-95 [DOI: 10.1016/S0378-1119(99)00252-8]
20. Weisenberger D.J.; Velicescu M.; Preciado-Lopez M.A.; Gonzales F.A.; Tsai Y.C.; Liang G.; Jones P.A.; Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene 2002,298(1),91-99 [DOI: 10.1016/S0378-1119(02)00976-9]
21. Yanagisawa Y.; Ito E.; Yuasa Y.; Maruyama K.; The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochim Biophys Acta Gene Struct Expr 2002,1577(3),457-465 [DOI: 10.1016/S0167-4781(02)00482-7]
22. Uysal F.; Akkoyunlu G.; Ozturk S.; Dynamic expression of DNA methyltransferases (DNMTs) in oocytes and early embryos. Biochimie 2015,116,103-113 [DOI: 10.1016/j.biochi.2015.06.019]
23. Ren W.; Gao L.; Song J.; Structural basis of DNMT1 and DNMT3A-Mediated DNA methylation. Genes 2018,9(12),620 [DOI: 10.3390/genes9120620]
24. Zeng Y.; Chen T.; DNA methylation reprogramming during mammalian development. Genes 2019,10(4),257 [DOI: 10.3390/genes10040257]
25. Chen Z.; Zhang Y.; Role of mammalian DNA methyltransferases in development. Annu Rev Biochem 2020,89(1),135-158 [DOI: 10.1146/annurev-biochem-103019-102815]
26. Baubec T.; Colombo D.F.; Wirbelauer C.; Schmidt J.; Burger L.; Krebs A.R.; Akalin A.; Schübeler D.; Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature 2015,520(7546),243-247 [DOI: 10.1038/nature14176]
27. Dhayalan A.; Rajavelu A.; Rathert P.; Tamas R.; Jurkowska R.Z.; Ragozin S.; Jeltsch A.; The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J Biol Chem 2010,285(34),26114-26120 [DOI: 10.1074/jbc.M109.089433]
28. Sendžikaitė G.; Hanna, C.W.; Stewart-Morgan, K.R.; Ivanova, E.; Kelsey, G. A DNMT3A PWWP mutation leads to methylation of bivalent chromatin and growth retardation in mice. Nat Commun 2019,10(1),1884 [DOI: 10.1038/s41467-019-09713-w]
29. Guo X.; Wang L.; Li J.; Ding Z.; Xiao J.; Yin X.; He S.; Shi P.; Dong L.; Li G.; Tian C.; Wang J.; Cong Y.; Xu Y.; Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature 2015,517(7536),640-644 [DOI: 10.1038/nature13899]
30. Zhang Y.; Jurkowska R.; Soeroes S.; Rajavelu A.; Dhayalan A.; Bock I.; Rathert P.; Brandt O.; Reinhardt R.; Fischle W.; Jeltsch A.; Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res 2010,38(13),4246-4253 [DOI: 10.1093/nar/gkq147]
31. Li B.Z.; Huang Z.; Cui Q.Y.; Song X.H.; Du L.; Jeltsch A.; Chen P.; Li G.; Li E.; Xu G.L.; Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase. Cell Res 2011,21(8),1172-1181 [DOI: 10.1038/cr.2011.92]
32. Saravanaraman P.; Selvam M.; Ashok C.; Srijyothi L.; Baluchamy S.; De novo methyltransferases: Potential players in diseases and new directions for targeted therapy. Biochimie 2020,176,85-102 [DOI: 10.1016/j.biochi.2020.07.004]
33. Lyko F.; The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. Nat Rev Genet 2018,19(2),81-92 [DOI: 10.1038/nrg.2017.80]
34. Jeltsch A.; Jurkowska R.Z.; Allosteric control of mammalian DNA methyltransferases – a new regulatory paradigm. Nucleic Acids Res 2016,44(18),8556-8575 [DOI: 10.1093/nar/gkw723]
35. Gowher H.; Jeltsch A.; Mammalian DNA methyltransferases: New discoveries and open questions. Biochem Soc Trans 2018,46(5),1191-1202 [DOI: 10.1042/BST20170574]
36. Lukashevich O.V.; Cherepanova N.A.; Jurkovska R.Z.; Jeltsch A.; Gromova E.S.; Conserved motif VIII of murine DNA methyltransferase Dnmt3a is essential for methylation activity. BMC Biochem 2016,17(1),7 [DOI: 10.1186/s12858-016-0064-y]
37. Fatemi M.; Hermann A.; Pradhan S.; Jeltsch A.; The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. J Mol Biol 2001,309(5),1189-1199 [DOI: 10.1006/jmbi.2001.4709]
38. Margot J.B.; Ehrenhofer-Murray A.E.; Leonhardt H.; Interactions within the mammalian DNA methyltransferase family. BMC Mol Biol 2003,4(1),7 [DOI: 10.1186/1471-2199-4-7]
39. Xu T.H.; Liu M.; Zhou X.E.; Liang G.; Zhao G.; Xu H.E.; Melcher K.; Jones P.A.; Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B. Nature 2020,586(7827),151-155 [DOI: 10.1038/s41586-020-2747-1]
40. Yarychkivska O.; Tavana O.; Gu W.; Bestor T.H.; Independent functions of DNMT1 and USP7 at replication foci. Epigenet Chromat 2018,11(1),9 [DOI: 10.1186/s13072-018-0179-z]
41. Yarychkivska O.; Shahabuddin Z.; Comfort N.; Boulard M.; Bestor T.H.; BAH domains and a histone-like motif in DNA methyltransferase 1 (DNMT1) regulate de novo and maintenance methylation in vivo. J Biol Chem 2018,293(50),19466-19475 [DOI: 10.1074/jbc.RA118.004612]
42. Yu J.; Xie T.; Wang Z.; Wang X.; Zeng S.; Kang Y.; Hou T.; DNA methyltransferases: Emerging targets for the discovery of inhibitors as potent anticancer drugs. Drug Discov Today 2019,24(12),2323-2331 [DOI: 10.1016/j.drudis.2019.08.006]
43. Zhang Z.M.; Liu S.; Lin K.; Luo Y.; Perry J.J.; Wang Y.; Song J.; Crystal structure of human DNA methyltransferase 1. J Mol Biol 2015,427(15),2520-2531 [DOI: 10.1016/j.jmb.2015.06.001]
44. Xie T.; Yu J.; Fu W.; Wang Z.; Xu L.; Chang S.; Wang E.; Zhu F.; Zeng S.; Kang Y.; Hou T.; Insight into the selective binding mechanism of DNMT1 and DNMT3A inhibitors: A molecular simulation study. Phys Chem Chem Phys 2019,21(24),12931-12947 [DOI: 10.1039/C9CP02024A]
45. Ley T.J.; Ding L.; Walter M.J.; McLellan M.D.; Lamprecht T.; Larson D.E.; Kandoth C.; Payton J.E.; Baty J.; Welch J.; Harris C.C.; Lichti C.F.; Townsend R.R.; Fulton R.S.; Dooling D.J.; Koboldt D.C.; Schmidt H.; Zhang Q.; Osborne J.R.; Lin L.; O’Laughlin M.; McMichael J.F.; Delehaunty K.D.; McGrath S.D.; Fulton L.A.; Magrini V.J.; Vickery T.L.; Hundal J.; Cook L.L.; Conyers J.J.; Swift G.W.; Reed J.P.; Alldredge P.A.; Wylie T.; Walker J.; Kalicki J.; Watson M.A.; Heath S.; Shannon W.D.; Varghese N.; Nagarajan R.; Westervelt P.; Tomasson M.H.; Link D.C.; Graubert T.A.; DiPersio J.F.; Mardis E.R.; Wilson R.K.; DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010,363(25),2424-2433 [DOI: 10.1056/NEJMoa1005143]
46. Yan X.J.; Xu J.; Gu Z.H.; Pan C.M.; Lu G.; Shen Y.; Shi J.Y.; Zhu Y.M.; Tang L.; Zhang X.W.; Liang W.X.; Mi J.Q.; Song H.D.; Li K.Q.; Chen Z.; Chen S.J.; Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011,43(4),309-315 [DOI: 10.1038/ng.788]
47. Walter M.J.; Ding L.; Shen D.; Shao J.; Grillot M.; McLellan M.; Fulton R.; Schmidt H.; Kalicki-Veizer J.; O’Laughlin M.; Kandoth C.; Baty J.; Westervelt P.; DiPersio J.F.; Mardis E.R.; Wilson R.K.; Ley T.J.; Graubert T.A.; Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011,25(7),1153-1158 [DOI: 10.1038/leu.2011.44]
48. Xu J.; Wang Y.Y.; Dai Y.J.; Zhang W.; Zhang W.N.; Xiong S.M.; Gu Z.H.; Wang K.K.; Zeng R.; Chen Z.; Chen S.J.; DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci USA 2014,111(7),2620-2625 [DOI: 10.1073/pnas.1400150111]
49. Zhao Z.; Wu Q.; Cheng J.; Qiu X.; Zhang J.; Fan H.; Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. J Biomed Biotechnol 2010,2010,1-10 [DOI: 10.1155/2010/737535]
50. Mayle A.; Yang L.; Rodriguez B.; Zhou T.; Chang E.; Curry C.V.; Challen G.A.; Li W.; Wheeler D.; Rebel V.I.; Goodell M.A.; Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 2015,125(4),629-638 [DOI: 10.1182/blood-2014-08-594648]
51. Yang L.; Rodriguez B.; Mayle A.; Park H.J.; Lin X.; Luo M.; Jeong M.; Curry C.V.; Kim S.B.; Ruau D.; Zhang X.; Zhou T.; Zhou M.; Rebel V.I.; Challen G.A.; Göttgens B.; Lee J.S.; Rau R.; Li W.; Goodell M.A.; DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias. Cancer Cell 2016,29(6),922-934 [DOI: 10.1016/j.ccell.2016.05.003]
52. Wang L.; Yao J.; Sun H.; He K.; Tong D.; Song T.; Huang C.; MicroRNA-101 suppresses progression of lung cancer through the PTEN/AKT signaling pathway by targeting DNA methyltransferase 3A. Oncol Lett 2017,13(1),329-338 [DOI: 10.3892/ol.2016.5423]
53. Fabbri M.; Garzon R.; Cimmino A.; Liu Z.; Zanesi N.; Callegari E.; Liu S.; Alder H.; Costinean S.; Fernandez-Cymering C.; Volinia S.; Guler G.; Morrison C.D.; Chan K.K.; Marcucci G.; Calin G.A.; Huebner K.; Croce C.M.; MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007,104(40),15805-15810 [DOI: 10.1073/pnas.0707628104]
54. Viré E.; Brenner C.; Deplus R.; Blanchon L.; Fraga M.; Didelot C.; Morey L.; Van Eynde A.; Bernard D.; Vanderwinden J.M.; Bollen M.; Esteller M.; Di Croce L.; de Launoit Y.; Fuks F.; The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006,439(7078),871-874 [DOI: 10.1038/nature04431]
55. Schlesinger Y.; Straussman R.; Keshet I.; Farkash S.; Hecht M.; Zimmerman J.; Eden E.; Yakhini Z.; Ben-Shushan E.; Reubinoff B.E.; Bergman Y.; Simon I.; Cedar H.; Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007,39(2),232-236 [DOI: 10.1038/ng1950]
56. Jang K.; Kim M.; Gilbert C.A.; Simpkins F.; Ince T.A.; Slingerland J.M.; VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. EMBO Mol Med 2017,9(3),304-318 [DOI: 10.15252/emmm.201606840]
57. Samowitz W.S.; Curtin K.; Ma K.; Edwards S.; Schaffer D.; Leppert M.F.; Slattery M.L.; Prognostic significance ofp53 mutations in colon cancer at the population level. Int J Cancer 2002,99(4),597-602 [DOI: 10.1002/ijc.10405]
58. Wang Y.A.; Kamarova Y.; Shen K.C.; Jiang Z.; Hahn M.J.; Wang Y.; Brooks S.C.; DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression. Cancer Biol Ther 2005,4(10),1138-1143 [DOI: 10.4161/cbt.4.10.2073]
59. Mizuno S.; Chijiwa T.; Okamura T.; Akashi K.; Fukumaki Y.; Niho Y.; Sasaki H.; Expression of DNA methyltransferases DNMT1,3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001,97(5),1172-1179 [DOI: 10.1182/blood.V97.5.1172]
60. Berg T.; Guo Y.; Abdelkarim M.; Fliegauf M.; Lübbert M.; Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk Res 2007,31(4),497-506 [DOI: 10.1016/j.leukres.2006.08.008]
61. Chan M.W.; Chan L.W.; Tang N.L.; Tong J.H.; Lo K.W.; Lee T.L.; Cheung H.Y.; Wong W.S.; Chan P.S.; Lai F.M.; To K.F.; Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002,8(2),464-470 [PMID: 11839665]
62. Liang J.T.; Chang K.J.; Chen J.C.; Lee C.C.; Cheng Y.M.; Hsu H.C.; Wu M.S.; Wang S.M.; Lin J.T.; Cheng A.L.; Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: Association with DNA replication error and shorter survival. Oncology 1999,57(2),149-156 [DOI: 10.1159/000012023]
63. Suzuki M.; Shigematsu H.; Shames D.S.; Sunaga N.; Takahashi T.; Shivapurkar N.; Iizasa T.; Frenkel E.P.; Minna J.D.; Fujisawa T.; Gazdar A.F.; Retraction Note: DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 2013,109(12),3132 [DOI: 10.1038/bjc.2013.776]
64. Lu D.; Ma Y.; Zhu A.; Han Y.; An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis. Oncotarget 2017,8(13),22166-22174 [DOI: 10.18632/oncotarget.13125]
65. Stresemann C.; Lyko F.; Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008,123(1),8-13 [DOI: 10.1002/ijc.23607]
66. Castillo-Aguilera O.; Depreux P.; Halby L.; Arimondo P.; Goossens L.; DNA methylation targeting: The DNMT/HMT crosstalk challenge. Biomolecules 2017,7(4),3 [DOI: 10.3390/biom7010003]
67. Erdmann A.; Menon Y.; Gros C.; Molinier N.; Novosad N.; Samson A.; Gregoire J.M.; Long C.; Ausseil F.; Halby L.; Arimondo P.B.; Design and synthesis of new non nucleoside inhibitors of DNMT3A. Bioorg Med Chem 2015,23(17),5946-5953 [DOI: 10.1016/j.bmc.2015.06.066]
68. Sergeev A.; Vorobyov A.; Yakubovskaya M.; Kirsanova O.; Gromova E.; Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a. Bioorg Med Chem Lett 2020,30(16),127296 [DOI: 10.1016/j.bmcl.2020.127296]
69. Shao Z.; Xu P.; Xu W.; Li L.; Liu S.; Zhang R.; Liu Y.C.; Zhang C.; Chen S.; Luo C.; Discovery of novel DNA methyltransferase 3A inhibitors via structure-based virtual screening and biological assays. Bioorg Med Chem Lett 2017,27(2),342-346 [DOI: 10.1016/j.bmcl.2016.11.023]
70. Yu J.; Chai X.; Pang J.; Wang Z.; Zhao H.; Xie T.; Xu L.; Sheng R.; Li D.; Zeng S.; Hou T.; Kang Y.; Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A. Eur J Med Chem 2022,242,114646 [DOI: 10.1016/j.ejmech.2022.114646]
71. Rilova E.; Erdmann A.; Gros C.; Masson V.; Aussagues Y.; Poughon-Cassabois V.; Rajavelu A.; Jeltsch A.; Menon Y.; Novosad N.; Gregoire J.M.; Vispé S.; Schambel P.; Ausseil F.; Sautel F.; Arimondo P.B.; Cantagrel F.; Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. ChemMedChem 2014,9(3),590-601 [DOI: 10.1002/cmdc.201300420]
72. Valente S.; Liu Y.; Schnekenburger M.; Zwergel C.; Cosconati S.; Gros C.; Tardugno M.; Labella D.; Florean C.; Minden S.; Hashimoto H.; Chang Y.; Zhang X.; Kirsch G.; Novellino E.; Arimondo P.B.; Miele E.; Ferretti E.; Gulino A.; Diederich M.; Cheng X.; Mai A.; Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells. J Med Chem 2014,57(3),701-713 [DOI: 10.1021/jm4012627]
73. Erdmann A.; Menon Y.; Gros C.; Masson V.; Aussagues Y.; Ausseil F.; Novosad N.; Schambel P.; Baltas M.; Arimondo P.B.; Identification and optimization of hydrazone-gallate derivatives as specific inhibitors of DNA methyltransferase 3A. Future Med Chem 2016,8(4),373-380 [DOI: 10.4155/fmc.15.192]
74. Castellano S.; Kuck D.; Viviano M.; Yoo J.; López-Vallejo F.; Conti P.; Tamborini L.; Pinto A.; Medina-Franco J.L.; Sbardella G.; Synthesis and biochemical evaluation of δ(2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors. J Med Chem 2011,54(21),7663-7677 [DOI: 10.1021/jm2010404]
75. Gros C.; Fleury L.; Nahoum V.; Faux C.; Valente S.; Labella D.; Cantagrel F.; Rilova E.; Bouhlel M.A.; David-Cordonnier M.H.; Dufau I.; Ausseil F.; Mai A.; Mourey L.; Lacroix L.; Arimondo P.B.; New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J Biol Chem 2015,290(10),6293-6302 [DOI: 10.1074/jbc.M114.594671]
76. Halby L.; Menon Y.; Rilova E.; Pechalrieu D.; Masson V.; Faux C.; Bouhlel M.A.; David-Cordonnier M.H.; Novosad N.; Aussagues Y.; Samson A.; Lacroix L.; Ausseil F.; Fleury L.; Guianvarc’h D.; Ferroud C.; Arimondo P.B.; Rational design of bisubstrate-type analogues as inhibitors of DNA methyltransferases in cancer Cells. J Med Chem 2017,60(11),4665-4679 [DOI: 10.1021/acs.jmedchem.7b00176]
77. Siedlecki P.; Boy R.G.; Musch T.; Brueckner B.; Suhai S.; Lyko F.; Zielenkiewicz P.; Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006,49(2),678-683 [DOI: 10.1021/jm050844z]
78. Ceccaldi A.; Rajavelu A.; Champion C.; Rampon C.; Jurkowska R.; Jankevicius G.; Sénamaud-Beaufort C.; Ponger L.; Gagey N.; Dali Ali H.; Tost J.; Vriz S.; Ros S.; Dauzonne D.; Jeltsch A.; Guianvarc’h D.; Arimondo P.B.; C5-DNA methyltransferase inhibitors: From screening to effects on zebrafish embryo development. ChemBioChem 2011,12(9),1337-1345 [DOI: 10.1002/cbic.201100130]
79. Ceccaldi A.; Rajavelu A.; Ragozin S.; Sénamaud-Beaufort C.; Bashtrykov P.; Testa N.; Dali-Ali H.; Maulay-Bailly C.; Amand S.; Guianvarc’h D.; Jeltsch A.; Arimondo P.B.; Identification of novel inhibitors of DNA methylation by screening of a chemical library. ACS Chem Biol 2013,8(3),543-548 [DOI: 10.1021/cb300565z]
80. Fagan R.L.; Cryderman D.E.; Kopelovich L.; Wallrath L.L.; Brenner C.; Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1. J Biol Chem 2013,288(33),23858-23867 [DOI: 10.1074/jbc.M113.480517]
81. Kilgore J.A.; Du X.; Melito L.; Wei S.; Wang C.; Chin H.G.; Posner B.; Pradhan S.; Ready J.M.; Williams N.S.; Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. J Biol Chem 2013,288(27),19673-19684 [DOI: 10.1074/jbc.M112.443895]
82. Garella D.; Atlante S.; Borretto E.; Cocco M.; Giorgis M.; Costale A.; Stevanato L.; Miglio G.; Cencioni C.; Fernández-de Gortari E.; Medina-Franco J.L.; Spallotta F.; Gaetano C.; Bertinaria M.; Design and synthesis of N -benzoyl amino acid derivatives as DNA methylation inhibitors. Chem Biol Drug Des 2016,88(5),664-676 [DOI: 10.1111/cbdd.12794]
83. Rondelet G.; Fleury L.; Faux C.; Masson V.; Dubois J.; Arimondo P.B.; Willems L.; Wouters J.; Inhibition studies of DNA methyltransferases by maleimide derivatives of RG108 as non-nucleoside inhibitors. Future Med Chem 2017,9(13),1465-1481 [DOI: 10.4155/fmc-2017-0074]
84. Saldívar-González F.I.; Gómez-García A.; Chávez-Ponce de León D.E.; Sánchez-Cruz N.; Ruiz-Rios J.; Pilón-Jiménez B.A.; Medina-Franco J.L.; Inhibitors of DNA methyltransferases from natural sources: A computational perspective. Front Pharmacol 2018,9,1144 [DOI: 10.3389/fphar.2018.01144]
85. San José-Enériz E.; Agirre X.; Rabal O.; Vilas-Zornoza A.; Sanchez-Arias J.A.; Miranda E.; Ugarte A.; Roa S.; Paiva B.; Estella-Hermoso de Mendoza A.; Alvarez R.M.; Casares N.; Segura V.; Martín-Subero J.I.; Ogi F.X.; Soule P.; Santiveri C.M.; Campos-Olivas R.; Castellano G.; de Barrena M.G.F.; Rodriguez-Madoz J.R.; García-Barchino M.J.; Lasarte J.J.; Avila M.A.; Martinez-Climent J.A.; Oyarzabal J.; Prosper F.; Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun 2017,8(1),15424 [DOI: 10.1038/ncomms15424]
86. Leroy M.; Mélin L.; LaPlante S.R.; Medina-Franco J.L.; Gagnon A.; Synthesis of NSC 106084 and NSC 14778 and evaluation of their DNMT inhibitory activity. Bioorg Med Chem Lett 2019,29(6),826-831 [DOI: 10.1016/j.bmcl.2019.01.022]

Grants

1. 82273793/National Natural Science Foundation of China
2. LJKZZ20220108/Key Research Project of the Department of Education of Liaoning Province
3. 2019M661132/China Postdoctoral Science Foundation
4. LJKQZ20222351/foundation of Liaoning Provincial Department of Education

MeSH Term

Chemicals